Efficacy of immune checkpoint inhibitors (ICIs) in rare histological variants of bladder cancer. Read more about Efficacy of immune checkpoint inhibitors (ICIs) in rare histological variants of bladder cancer.
Disparities in receipt of molecular imaging in biochemical recurrent prostate cancer. Read more about Disparities in receipt of molecular imaging in biochemical recurrent prostate cancer.
ADRB2 expression in progressive metastatic castration-resistant prostate cancer. Read more about ADRB2 expression in progressive metastatic castration-resistant prostate cancer.
Phase I prospective trial of TAS-102 (trifluride and tipiracil) and radioembolization with 90Y resin microspheres for chemo-refractory colorectal liver metastases. Read more about Phase I prospective trial of TAS-102 (trifluride and tipiracil) and radioembolization with 90Y resin microspheres for chemo-refractory colorectal liver metastases.
Patient-derived organoids for personalized drug screening in intrahepatic cholangiocarcinoma. Read more about Patient-derived organoids for personalized drug screening in intrahepatic cholangiocarcinoma.
Mixed methods comparison of functional decline during chemotherapy, immunotherapy (IO), and/or targeted therapy in older adults with non-small cell lung cancer (NSCLC). Read more about Mixed methods comparison of functional decline during chemotherapy, immunotherapy (IO), and/or targeted therapy in older adults with non-small cell lung cancer (NSCLC).
Prospective cardiac function monitoring in immunotherapy-treated patients. Read more about Prospective cardiac function monitoring in immunotherapy-treated patients.
Phase 1/1B trial to assess the activity of entrectinib in children and adolescents with recurrent or refractory solid tumors including central nervous system (CNS) tumors. Read more about Phase 1/1B trial to assess the activity of entrectinib in children and adolescents with recurrent or refractory solid tumors including central nervous system (CNS) tumors.
A phase Ib trial of the cyclin-dependent kinase inhibitor dinaciclib (dina) in combination with pembrolizumab (P) in patients with advanced triple-negative breast cancer (TNBC). Read more about A phase Ib trial of the cyclin-dependent kinase inhibitor dinaciclib (dina) in combination with pembrolizumab (P) in patients with advanced triple-negative breast cancer (TNBC).
A regulatory program that promotes metastasis in colorectal cancer (CRC) through modulation of mRNA stability. Read more about A regulatory program that promotes metastasis in colorectal cancer (CRC) through modulation of mRNA stability.
